Jan 16 (Reuters) - Transgene Sa:
* ‍FIRST PATIENT DOSED IN A PHASE 2 TRIAL WITH TRANSGENE‘S TG4010 + NIVOLUMAB + CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF LUNG CANCER (NSCLC)​
* ‍FIRST RESULTS EXPECTED IN H2 2018​ * ‍THIS MULTI-CENTER SINGLE-ARM TRIAL WILL ENROLL UP TO 39 PATIENTS BOTH IN USA AND EUROPE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 